You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSulfisoxazole
Accession NumberDB00263  (APRD00595)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. [PubChem]
Structure
Thumb
Synonyms
3,4-Dimethyl-5-sulfanilamidoisoxazole
3,4-Dimethyl-5-sulfonamidoisoxazole
3,4-Dimethyl-5-sulphanilamidoisoxazole
3,4-Dimethyl-5-sulphonamidoisoxazole
3,4-Dimethylisoxazole-5-sulfanilamide
3,4-Dimethylisoxazole-5-sulphanilamide
4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide
4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide
5-(4-Aminophenylsulfonamido)-3,4-dimethylisoxazole
5-(P-Aminobenzenesulfonamido)-3,4-dimethylisoxazole
5-(P-Aminobenzenesulphonamido)-3,4-dimethylisoxazole
5-Sulfanilamido-3,4-dimethylisoxazole
5-Sulphanilamido-3,4-dimethyl-isoxazole
N'-(3,4)dimethylisoxazol-5-yl-sulphanilamide
N(1)-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide
N(1)-(3,4-Dimethyl-5-isoxazolyl)sulphanilamide
Sulfadimethylisoxazole
Sulfafurazol
Sulfafurazole
Sulfafurazolum
Sulfaisoxazole
Sulfasoxazole
Sulfisonazole
Sulfisoxasole
Sulfisoxazol
Sulfofurazole
Sulphadimethylisoxazole
Sulphafurazol
Sulphafurazole
Sulphaisoxazole
Sulphisoxazol
Sulphofurazole
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-soxazole 500mgtablet500 mgoralNovopharm Limited1967-12-312005-08-10Canada
Sulfisoxazole 500mg Tabletstablet500 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Sulfizole Tab 500mgtablet500 mgoralIcn Canada Ltd.1963-12-312005-04-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Sulfisoxazole Tab 500mgtablet500 mgoralApotex Inc1977-12-31Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GantrisinRoche
NeoxazolNot Available
Brand mixtures
NameLabellerIngredients
Erythromycin Ethylsuccinate and Sulfisoxazole AcetylRebel Distributors Corp
PediazoleAmdipharm Limited
Salts
Name/CASStructureProperties
Acetyl sulfisoxazole
ThumbNot applicableDBSALT000856
Sulfisoxazole diolamine
ThumbNot applicableDBSALT001376
Categories
UNII740T4C525W
CAS number127-69-5
WeightAverage: 267.304
Monoisotopic: 267.067761987
Chemical FormulaC11H13N3O3S
InChI KeyInChIKey=NHUHCSRWZMLRLA-UHFFFAOYSA-N
InChI
InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
IUPAC Name
4-amino-N-(dimethyl-1,2-oxazol-5-yl)benzene-1-sulfonamide
SMILES
CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentAminobenzenesulfonamides
Alternative Parents
Substituents
  • Aminobenzenesulfonamide
  • Sulfonylaniline
  • Substituted aniline
  • Aniline
  • Primary aromatic amine
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Oxazole
  • Isoxazole
  • Azole
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Primary amine
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.
PharmacodynamicsSulfisoxazole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
Mechanism of actionSulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationThe mean urinary excretion recovery following oral administration of sulfisoxazole is 97% within 48 hours, of which 52% is intact drug, with the remaining as the N4-acetylated metabolite. It is excreted in human milk.
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=6800 mg/kg (Orally in mice)
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9908
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6046
P-glycoprotein substrateNon-substrate0.8891
P-glycoprotein inhibitor INon-inhibitor0.9357
P-glycoprotein inhibitor IINon-inhibitor0.9698
Renal organic cation transporterNon-inhibitor0.9322
CYP450 2C9 substrateNon-substrate0.8056
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.9621
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9358
CYP450 2C19 inhibitorNon-inhibitor0.9292
CYP450 3A4 inhibitorNon-inhibitor0.9386
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8037
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7969
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.4586 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9896
hERG inhibition (predictor II)Non-inhibitor0.9442
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Mk laboratories inc
  • Alra laboratories inc
  • Parke davis div warner lambert co
  • Barr laboratories inc
  • Heather drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lannett co inc
  • Lederle laboratories div american cyanamid co
  • Pharmeral inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Solvay pharmaceuticals
  • Sola barnes hind
Packagers
Dosage forms
FormRouteStrength
Tabletoral500 mg
Granule, for suspensionoral
Powder for suspensionoral
Prices
Unit descriptionCostUnit
Sulfisoxazole crystals1.01USD g
Sulfazine EC 500 mg Enteric Coated Tabs0.42USD tab
Sulfazine ec 500 mg tablet0.38USD tablet
Sulfazine 500 mg tablet0.25USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191 °CPhysProp
water solubility300 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.01HANSCH,C ET AL. (1995)
logS-2.91ADME Research, USCD
pKa5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.313 mg/mLALOGPS
logP1.14ALOGPS
logP0.73ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)5.8ChemAxon
pKa (Strongest Basic)2.17ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area98.22 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity67.92 m3·mol-1ChemAxon
Polarizability26.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.71 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesJ01EB05S01AB02
AHFS Codes
  • 08:12.20
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Sulfisoxazole.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Sulfisoxazole.
AcarboseAcarbose may increase the hypoglycemic activities of Sulfisoxazole.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Sulfisoxazole.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sulfisoxazole.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Sulfisoxazole.
AcetohexamideSulfisoxazole may increase the hypoglycemic activities of Acetohexamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Sulfisoxazole.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Sulfisoxazole.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Sulfisoxazole.
AicarAicar may increase the hypoglycemic activities of Sulfisoxazole.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Sulfisoxazole.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Sulfisoxazole.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Sulfisoxazole.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Sulfisoxazole.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Sulfisoxazole.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Sulfisoxazole.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Sulfisoxazole.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Sulfisoxazole.
AlogliptinAlogliptin may increase the hypoglycemic activities of Sulfisoxazole.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Sulfisoxazole.
AlosetronThe metabolism of Alosetron can be decreased when combined with Sulfisoxazole.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Sulfisoxazole.
AmantadineAmantadine may increase the QTc-prolonging activities of Sulfisoxazole.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Sulfisoxazole.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Sulfisoxazole.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Sulfisoxazole.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Sulfisoxazole.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Sulfisoxazole.
AmiodaroneSulfisoxazole may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Sulfisoxazole can be decreased when combined with Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Sulfisoxazole.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Sulfisoxazole.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Sulfisoxazole.
AmoxapineAmoxapine may increase the hypoglycemic activities of Sulfisoxazole.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Sulfisoxazole.
AnagrelideSulfisoxazole may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Sulfisoxazole.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Sulfisoxazole.
ApomorphineApomorphine may increase the QTc-prolonging activities of Sulfisoxazole.
ApremilastThe metabolism of Apremilast can be decreased when combined with Sulfisoxazole.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Sulfisoxazole.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Sulfisoxazole.
ArformoterolArformoterol may increase the QTc-prolonging activities of Sulfisoxazole.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Sulfisoxazole.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Sulfisoxazole.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sulfisoxazole.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Sulfisoxazole.
Arsenic trioxideSulfisoxazole may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherSulfisoxazole may increase the QTc-prolonging activities of Artemether.
AsenapineSulfisoxazole may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Sulfisoxazole.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Sulfisoxazole.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Sulfisoxazole.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Sulfisoxazole.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Sulfisoxazole.
AvanafilThe metabolism of Avanafil can be decreased when combined with Sulfisoxazole.
AxitinibThe metabolism of Axitinib can be decreased when combined with Sulfisoxazole.
AzelastineThe metabolism of Azelastine can be decreased when combined with Sulfisoxazole.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Sulfisoxazole.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Sulfisoxazole.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Sulfisoxazole.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Sulfisoxazole.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Sulfisoxazole.
BenmoxinBenmoxin may increase the hypoglycemic activities of Sulfisoxazole.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Sulfisoxazole.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Sulfisoxazole.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Sulfisoxazole.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Sulfisoxazole.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Sulfisoxazole.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Sulfisoxazole.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Sulfisoxazole.
BortezomibBortezomib may increase the QTc-prolonging activities of Sulfisoxazole.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Sulfisoxazole.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Sulfisoxazole.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sulfisoxazole.
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Sulfisoxazole.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Sulfisoxazole.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Sulfisoxazole.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Sulfisoxazole.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Sulfisoxazole.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Sulfisoxazole.
BudesonideThe metabolism of Budesonide can be decreased when combined with Sulfisoxazole.
BuforminBuformin may increase the hypoglycemic activities of Sulfisoxazole.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Sulfisoxazole.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Sulfisoxazole.
BupropionThe metabolism of Bupropion can be decreased when combined with Sulfisoxazole.
BuserelinBuserelin may increase the QTc-prolonging activities of Sulfisoxazole.
BuspironeThe metabolism of Buspirone can be decreased when combined with Sulfisoxazole.
BusulfanThe metabolism of Busulfan can be decreased when combined with Sulfisoxazole.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Sulfisoxazole.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Sulfisoxazole.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Sulfisoxazole.
CaffeineThe metabolism of Caffeine can be decreased when combined with Sulfisoxazole.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Sulfisoxazole.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Sulfisoxazole.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Sulfisoxazole.
CandesartanThe metabolism of Candesartan can be decreased when combined with Sulfisoxazole.
CapecitabineThe metabolism of Sulfisoxazole can be decreased when combined with Capecitabine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Sulfisoxazole.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Sulfisoxazole.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Sulfisoxazole.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Sulfisoxazole.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Sulfisoxazole.
CastanospermineCastanospermine may increase the hypoglycemic activities of Sulfisoxazole.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Sulfisoxazole.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Sulfisoxazole.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Sulfisoxazole.
CeritinibThe serum concentration of Sulfisoxazole can be increased when it is combined with Ceritinib.
CeritinibSulfisoxazole may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Sulfisoxazole.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Sulfisoxazole.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Sulfisoxazole.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Sulfisoxazole.
ChloroquineChloroquine may increase the QTc-prolonging activities of Sulfisoxazole.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Sulfisoxazole.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Sulfisoxazole.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Sulfisoxazole.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Sulfisoxazole.
ChlorpropamideSulfisoxazole may increase the hypoglycemic activities of Chlorpropamide.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Sulfisoxazole.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Sulfisoxazole.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Sulfisoxazole.
CiglitazoneCiglitazone may increase the hypoglycemic activities of Sulfisoxazole.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Sulfisoxazole.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Sulfisoxazole.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Sulfisoxazole.
CiprofloxacinSulfisoxazole may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideSulfisoxazole may increase the QTc-prolonging activities of Cisapride.
CitalopramCitalopram may increase the hypoglycemic activities of Sulfisoxazole.
CitalopramSulfisoxazole may increase the QTc-prolonging activities of Citalopram.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Sulfisoxazole.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Sulfisoxazole.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Sulfisoxazole.
ClobazamThe metabolism of Clobazam can be decreased when combined with Sulfisoxazole.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Sulfisoxazole.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Sulfisoxazole.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Sulfisoxazole.
ClomipramineClomipramine may increase the hypoglycemic activities of Sulfisoxazole.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Sulfisoxazole.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Sulfisoxazole.
ClonidineThe metabolism of Clonidine can be decreased when combined with Sulfisoxazole.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Sulfisoxazole.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Sulfisoxazole.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Sulfisoxazole.
ClotrimazoleThe metabolism of Sulfisoxazole can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Sulfisoxazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Sulfisoxazole.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Sulfisoxazole.
CocaineThe metabolism of Cocaine can be decreased when combined with Sulfisoxazole.
CodeineThe metabolism of Codeine can be decreased when combined with Sulfisoxazole.
ColchicineThe metabolism of Colchicine can be decreased when combined with Sulfisoxazole.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Sulfisoxazole.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Sulfisoxazole.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Sulfisoxazole.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Sulfisoxazole.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Sulfisoxazole.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Sulfisoxazole.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Sulfisoxazole.
CyclosporineSulfisoxazole may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Sulfisoxazole can be decreased when combined with Cyclosporine.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Sulfisoxazole.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Sulfisoxazole.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Sulfisoxazole.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Sulfisoxazole.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Sulfisoxazole.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Sulfisoxazole.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Sulfisoxazole.
DapoxetineDapoxetine may increase the hypoglycemic activities of Sulfisoxazole.
DapsoneThe metabolism of Dapsone can be decreased when combined with Sulfisoxazole.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Sulfisoxazole.
DarunavirThe metabolism of Darunavir can be decreased when combined with Sulfisoxazole.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Sulfisoxazole.
DasatinibDasatinib may increase the QTc-prolonging activities of Sulfisoxazole.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Sulfisoxazole.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Sulfisoxazole.
DegarelixDegarelix may increase the QTc-prolonging activities of Sulfisoxazole.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Sulfisoxazole.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Sulfisoxazole.
DesfluraneDesflurane may increase the QTc-prolonging activities of Sulfisoxazole.
DesipramineDesipramine may increase the QTc-prolonging activities of Sulfisoxazole.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Sulfisoxazole.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Sulfisoxazole.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfisoxazole.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Sulfisoxazole.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Sulfisoxazole.
DiazepamThe metabolism of Diazepam can be decreased when combined with Sulfisoxazole.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Sulfisoxazole.
DicoumarolSulfisoxazole may increase the anticoagulant activities of Dicoumarol.
DiflunisalDiflunisal may increase the hypoglycemic activities of Sulfisoxazole.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Sulfisoxazole.
DigoxinThe metabolism of Digoxin can be decreased when combined with Sulfisoxazole.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Sulfisoxazole.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Sulfisoxazole.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Sulfisoxazole.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Sulfisoxazole.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Sulfisoxazole.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Sulfisoxazole.
DisopyramideSulfisoxazole may increase the QTc-prolonging activities of Disopyramide.
DisopyramideDisopyramide may increase the hypoglycemic activities of Sulfisoxazole.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Sulfisoxazole.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Sulfisoxazole.
DofetilideSulfisoxazole may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Sulfisoxazole.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Sulfisoxazole.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Sulfisoxazole.
DonepezilThe metabolism of Donepezil can be decreased when combined with Sulfisoxazole.
DopamineThe metabolism of Dopamine can be decreased when combined with Sulfisoxazole.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Sulfisoxazole.
DoxepinDoxepin may increase the QTc-prolonging activities of Sulfisoxazole.
DoxepinThe metabolism of Doxepin can be decreased when combined with Sulfisoxazole.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Sulfisoxazole.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Sulfisoxazole.
DronedaroneSulfisoxazole may increase the QTc-prolonging activities of Dronedarone.
DroperidolSulfisoxazole may increase the QTc-prolonging activities of Droperidol.
DulaglutideDulaglutide may increase the hypoglycemic activities of Sulfisoxazole.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Sulfisoxazole.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Sulfisoxazole.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Sulfisoxazole.
EliglustatSulfisoxazole may increase the QTc-prolonging activities of Eliglustat.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Sulfisoxazole.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Sulfisoxazole.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Sulfisoxazole.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Sulfisoxazole.
EpinastineThe metabolism of Epinastine can be decreased when combined with Sulfisoxazole.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Sulfisoxazole.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Sulfisoxazole.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Sulfisoxazole.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Sulfisoxazole.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Sulfisoxazole.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Sulfisoxazole.
EribulinEribulin may increase the QTc-prolonging activities of Sulfisoxazole.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Sulfisoxazole.
ErythromycinErythromycin may increase the QTc-prolonging activities of Sulfisoxazole.
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Sulfisoxazole.
EscitalopramEscitalopram may increase the hypoglycemic activities of Sulfisoxazole.
EscitalopramSulfisoxazole may increase the QTc-prolonging activities of Escitalopram.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Sulfisoxazole.
EstazolamThe metabolism of Estazolam can be decreased when combined with Sulfisoxazole.
EstradiolThe metabolism of Estradiol can be decreased when combined with Sulfisoxazole.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Sulfisoxazole.
EstramustineThe metabolism of Estramustine can be decreased when combined with Sulfisoxazole.
EstroneThe metabolism of Estrone can be decreased when combined with Sulfisoxazole.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Sulfisoxazole.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Sulfisoxazole.
EthanolThe metabolism of Ethanol can be decreased when combined with Sulfisoxazole.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Sulfisoxazole.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Sulfisoxazole.
Ethyl biscoumacetateSulfisoxazole may increase the anticoagulant activities of Ethyl biscoumacetate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Sulfisoxazole.
EtodolacThe metabolism of Etodolac can be decreased when combined with Sulfisoxazole.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Sulfisoxazole.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Sulfisoxazole.
EtoposideThe metabolism of Etoposide can be decreased when combined with Sulfisoxazole.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Sulfisoxazole.
EtravirineThe metabolism of Etravirine can be decreased when combined with Sulfisoxazole.
EverolimusThe metabolism of Everolimus can be decreased when combined with Sulfisoxazole.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Sulfisoxazole.
ExenatideExenatide may increase the hypoglycemic activities of Sulfisoxazole.
EzogabineEzogabine may increase the QTc-prolonging activities of Sulfisoxazole.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Sulfisoxazole.
FamotidineFamotidine may increase the QTc-prolonging activities of Sulfisoxazole.
FelbamateFelbamate may increase the QTc-prolonging activities of Sulfisoxazole.
FelbamateThe metabolism of Felbamate can be decreased when combined with Sulfisoxazole.
FelodipineThe metabolism of Felodipine can be decreased when combined with Sulfisoxazole.
FenfluramineFenfluramine may increase the hypoglycemic activities of Sulfisoxazole.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Sulfisoxazole.
FentanylThe metabolism of Fentanyl can be decreased when combined with Sulfisoxazole.
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Sulfisoxazole.
FinasterideThe metabolism of Finasteride can be decreased when combined with Sulfisoxazole.
FingolimodFingolimod may increase the QTc-prolonging activities of Sulfisoxazole.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Sulfisoxazole.
FlecainideSulfisoxazole may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Sulfisoxazole.
FloxuridineThe metabolism of Sulfisoxazole can be decreased when combined with Floxuridine.
FluconazoleFluconazole may increase the QTc-prolonging activities of Sulfisoxazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sulfisoxazole.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Sulfisoxazole.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Sulfisoxazole.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Sulfisoxazole.
FluorouracilThe metabolism of Sulfisoxazole can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the hypoglycemic activities of Sulfisoxazole.
FluoxetineSulfisoxazole may increase the QTc-prolonging activities of Fluoxetine.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Sulfisoxazole.
FlupentixolSulfisoxazole may increase the QTc-prolonging activities of Flupentixol.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Sulfisoxazole.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Sulfisoxazole.
FlutamideThe metabolism of Flutamide can be decreased when combined with Sulfisoxazole.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Sulfisoxazole.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Sulfisoxazole.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Sulfisoxazole.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Sulfisoxazole.
FormoterolFormoterol may increase the QTc-prolonging activities of Sulfisoxazole.
FormoterolThe metabolism of Formoterol can be decreased when combined with Sulfisoxazole.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Sulfisoxazole.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Sulfisoxazole.
FosphenytoinThe metabolism of Sulfisoxazole can be increased when combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Sulfisoxazole.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Sulfisoxazole.
Gadobenic acidSulfisoxazole may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Sulfisoxazole.
GalantamineThe metabolism of Galantamine can be decreased when combined with Sulfisoxazole.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Sulfisoxazole.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Sulfisoxazole.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Sulfisoxazole.
GemifloxacinSulfisoxazole may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideSulfisoxazole may increase the hypoglycemic activities of Glibornuride.
GliclazideSulfisoxazole may increase the hypoglycemic activities of Gliclazide.
GlimepirideSulfisoxazole may increase the hypoglycemic activities of Glimepiride.
GlipizideSulfisoxazole may increase the hypoglycemic activities of Glipizide.
GliquidoneSulfisoxazole may increase the hypoglycemic activities of Gliquidone.
GlisoxepideSulfisoxazole may increase the hypoglycemic activities of Glisoxepide.
GlyburideSulfisoxazole may increase the hypoglycemic activities of Glyburide.
GoserelinGoserelin may increase the QTc-prolonging activities of Sulfisoxazole.
GranisetronGranisetron may increase the QTc-prolonging activities of Sulfisoxazole.
GranisetronThe metabolism of Granisetron can be decreased when combined with Sulfisoxazole.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Sulfisoxazole.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Sulfisoxazole.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Sulfisoxazole.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Sulfisoxazole.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Sulfisoxazole.
HalothaneThe metabolism of Halothane can be decreased when combined with Sulfisoxazole.
HexamethylenetetramineThe risk or severity of adverse effects can be increased when Hexamethylenetetramine is combined with Sulfisoxazole.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Sulfisoxazole.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Sulfisoxazole.
HistrelinHistrelin may increase the QTc-prolonging activities of Sulfisoxazole.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Sulfisoxazole.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Sulfisoxazole.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Sulfisoxazole.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Sulfisoxazole.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Sulfisoxazole.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Sulfisoxazole.
IbandronateIbandronate may increase the QTc-prolonging activities of Sulfisoxazole.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Sulfisoxazole.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Sulfisoxazole.
IbutilideSulfisoxazole may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Sulfisoxazole.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Sulfisoxazole resulting in a loss in efficacy.
IloperidoneSulfisoxazole may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Sulfisoxazole.
ImipramineImipramine may increase the QTc-prolonging activities of Sulfisoxazole.
ImipramineThe metabolism of Imipramine can be decreased when combined with Sulfisoxazole.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Sulfisoxazole.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Sulfisoxazole.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Sulfisoxazole.
IndalpineIndalpine may increase the hypoglycemic activities of Sulfisoxazole.
IndapamideIndapamide may increase the QTc-prolonging activities of Sulfisoxazole.
IndapamideThe metabolism of Indapamide can be decreased when combined with Sulfisoxazole.
IndinavirThe metabolism of Indinavir can be decreased when combined with Sulfisoxazole.
indisulamThe metabolism of indisulam can be decreased when combined with Sulfisoxazole.
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Sulfisoxazole.
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Sulfisoxazole.
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Sulfisoxazole.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Sulfisoxazole.
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Sulfisoxazole.
Insulin HumanInsulin Human may increase the hypoglycemic activities of Sulfisoxazole.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Sulfisoxazole.
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Sulfisoxazole.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Sulfisoxazole.
IproclozideIproclozide may increase the hypoglycemic activities of Sulfisoxazole.
IproniazidIproniazid may increase the hypoglycemic activities of Sulfisoxazole.
IrbesartanThe metabolism of Sulfisoxazole can be decreased when combined with Irbesartan.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Sulfisoxazole.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Sulfisoxazole.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Sulfisoxazole.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Sulfisoxazole.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Sulfisoxazole.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Sulfisoxazole.
IsradipineIsradipine may increase the QTc-prolonging activities of Sulfisoxazole.
IsradipineThe metabolism of Isradipine can be decreased when combined with Sulfisoxazole.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Sulfisoxazole.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Sulfisoxazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Sulfisoxazole.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Sulfisoxazole.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Sulfisoxazole.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Sulfisoxazole.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Sulfisoxazole.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Sulfisoxazole.
KetamineThe metabolism of Ketamine can be decreased when combined with Sulfisoxazole.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Sulfisoxazole.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Sulfisoxazole.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Sulfisoxazole.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Sulfisoxazole.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Sulfisoxazole.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Sulfisoxazole.
LanreotideSulfisoxazole may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Sulfisoxazole.
LapatinibLapatinib may increase the QTc-prolonging activities of Sulfisoxazole.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Sulfisoxazole.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Sulfisoxazole.
LeflunomideThe metabolism of Sulfisoxazole can be decreased when combined with Leflunomide.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Sulfisoxazole.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Sulfisoxazole.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Sulfisoxazole.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Sulfisoxazole.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Sulfisoxazole.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Sulfisoxazole.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Sulfisoxazole.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Sulfisoxazole.
LevofloxacinSulfisoxazole may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Sulfisoxazole.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Sulfisoxazole.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Sulfisoxazole.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Sulfisoxazole.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Sulfisoxazole.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Sulfisoxazole.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Sulfisoxazole.
LinagliptinLinagliptin may increase the hypoglycemic activities of Sulfisoxazole.
LiraglutideLiraglutide may increase the hypoglycemic activities of Sulfisoxazole.
LisurideThe metabolism of Lisuride can be decreased when combined with Sulfisoxazole.
LithiumLithium may increase the QTc-prolonging activities of Sulfisoxazole.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Sulfisoxazole.
LoperamideThe metabolism of Loperamide can be decreased when combined with Sulfisoxazole.
LopinavirSulfisoxazole may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Sulfisoxazole.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Sulfisoxazole.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Sulfisoxazole.
LosartanThe metabolism of Losartan can be decreased when combined with Sulfisoxazole.
LovastatinThe metabolism of Lovastatin can be decreased when combined with Sulfisoxazole.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Sulfisoxazole.
LumacaftorThe serum concentration of Sulfisoxazole can be decreased when it is combined with Lumacaftor.
LumefantrineSulfisoxazole may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Sulfisoxazole.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Sulfisoxazole.
MacitentanThe metabolism of Macitentan can be decreased when combined with Sulfisoxazole.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Sulfisoxazole.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Sulfisoxazole.
MebanazineMebanazine may increase the hypoglycemic activities of Sulfisoxazole.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Sulfisoxazole.
MecamylamineThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Mecamylamine.
MecaserminSulfisoxazole may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Sulfisoxazole.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Sulfisoxazole.
MefloquineMefloquine may increase the QTc-prolonging activities of Sulfisoxazole.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Sulfisoxazole.
MelatoninThe metabolism of Melatonin can be decreased when combined with Sulfisoxazole.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Sulfisoxazole.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Sulfisoxazole.
MesalazineMesalazine may increase the hypoglycemic activities of Sulfisoxazole.
MestranolThe metabolism of Mestranol can be decreased when combined with Sulfisoxazole.
MetforminMetformin may increase the hypoglycemic activities of Sulfisoxazole.
MethadoneMethadone may increase the QTc-prolonging activities of Sulfisoxazole.
MethadoneThe metabolism of Methadone can be decreased when combined with Sulfisoxazole.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Sulfisoxazole.
MethotrexateThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Methotrexate.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Sulfisoxazole.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Sulfisoxazole.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Sulfisoxazole.
Methylene blueMethylene blue may increase the hypoglycemic activities of Sulfisoxazole.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Sulfisoxazole.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Sulfisoxazole.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Sulfisoxazole.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Sulfisoxazole.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Sulfisoxazole.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Sulfisoxazole.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Sulfisoxazole.
MianserinThe metabolism of Mianserin can be decreased when combined with Sulfisoxazole.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Sulfisoxazole.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Sulfisoxazole.
MidazolamThe metabolism of Midazolam can be decreased when combined with Sulfisoxazole.
MifepristoneMifepristone may increase the QTc-prolonging activities of Sulfisoxazole.
MiglitolMiglitol may increase the hypoglycemic activities of Sulfisoxazole.
MiglustatMiglustat may increase the hypoglycemic activities of Sulfisoxazole.
MilnacipranMilnacipran may increase the hypoglycemic activities of Sulfisoxazole.
MinaprineMinaprine may increase the hypoglycemic activities of Sulfisoxazole.
MirabegronMirabegron may increase the QTc-prolonging activities of Sulfisoxazole.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Sulfisoxazole.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Sulfisoxazole.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Sulfisoxazole.
MitiglinideMitiglinide may increase the hypoglycemic activities of Sulfisoxazole.
MoclobemideMoclobemide may increase the hypoglycemic activities of Sulfisoxazole.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Sulfisoxazole.
ModafinilThe metabolism of Modafinil can be decreased when combined with Sulfisoxazole.
MoexiprilMoexipril may increase the QTc-prolonging activities of Sulfisoxazole.
MontelukastThe metabolism of Montelukast can be decreased when combined with Sulfisoxazole.
MorphineThe metabolism of Morphine can be decreased when combined with Sulfisoxazole.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Sulfisoxazole.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Sulfisoxazole.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sulfisoxazole.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Sulfisoxazole.
NaproxenThe metabolism of Naproxen can be decreased when combined with Sulfisoxazole.
NateglinideNateglinide may increase the hypoglycemic activities of Sulfisoxazole.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Sulfisoxazole.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Sulfisoxazole.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Sulfisoxazole.
NetupitantThe metabolism of Netupitant can be decreased when combined with Sulfisoxazole.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Sulfisoxazole.
NialamideNialamide may increase the hypoglycemic activities of Sulfisoxazole.
NicardipineNicardipine may increase the QTc-prolonging activities of Sulfisoxazole.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Sulfisoxazole.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Sulfisoxazole.
NicotineThe metabolism of Nicotine can be decreased when combined with Sulfisoxazole.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Sulfisoxazole.
NilotinibSulfisoxazole may increase the QTc-prolonging activities of Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Sulfisoxazole.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Sulfisoxazole.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Sulfisoxazole.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Sulfisoxazole.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Sulfisoxazole.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Sulfisoxazole.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Sulfisoxazole.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Sulfisoxazole.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Sulfisoxazole.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Sulfisoxazole.
OctamoxinOctamoxin may increase the hypoglycemic activities of Sulfisoxazole.
OctreotideOctreotide may increase the QTc-prolonging activities of Sulfisoxazole.
OctreotideSulfisoxazole may increase the hypoglycemic activities of Octreotide.
OfloxacinSulfisoxazole may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the hypoglycemic activities of Sulfisoxazole.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Sulfisoxazole.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Sulfisoxazole.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Sulfisoxazole.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Sulfisoxazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Sulfisoxazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Sulfisoxazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Sulfisoxazole.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Sulfisoxazole.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Sulfisoxazole.
OxandroloneOxandrolone may increase the hypoglycemic activities of Sulfisoxazole.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Sulfisoxazole.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Sulfisoxazole.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Sulfisoxazole.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Sulfisoxazole.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Sulfisoxazole.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Sulfisoxazole.
OxytocinOxytocin may increase the QTc-prolonging activities of Sulfisoxazole.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Sulfisoxazole.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Sulfisoxazole.
PaliperidoneSulfisoxazole may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Sulfisoxazole.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Sulfisoxazole.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Sulfisoxazole.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Sulfisoxazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Sulfisoxazole.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Sulfisoxazole.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Sulfisoxazole.
PargylinePargyline may increase the hypoglycemic activities of Sulfisoxazole.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Sulfisoxazole.
ParoxetineParoxetine may increase the hypoglycemic activities of Sulfisoxazole.
PasireotidePasireotide may increase the QTc-prolonging activities of Sulfisoxazole.
PasireotideSulfisoxazole may increase the hypoglycemic activities of Pasireotide.
PazopanibPazopanib may increase the QTc-prolonging activities of Sulfisoxazole.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Sulfisoxazole.
PegvisomantPegvisomant may increase the hypoglycemic activities of Sulfisoxazole.
PentamidineSulfisoxazole may increase the hypoglycemic activities of Pentamidine.
PerampanelThe metabolism of Perampanel can be decreased when combined with Sulfisoxazole.
PerflutrenSulfisoxazole may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Sulfisoxazole.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Sulfisoxazole.
PermethrinThe metabolism of Permethrin can be decreased when combined with Sulfisoxazole.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Sulfisoxazole.
PethidineThe metabolism of Pethidine can be decreased when combined with Sulfisoxazole.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Sulfisoxazole.
PhenelzinePhenelzine may increase the hypoglycemic activities of Sulfisoxazole.
PhenforminPhenformin may increase the hypoglycemic activities of Sulfisoxazole.
PhenindioneSulfisoxazole may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the hypoglycemic activities of Sulfisoxazole.
PhenobarbitalThe metabolism of Sulfisoxazole can be increased when combined with Phenobarbital.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Sulfisoxazole.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Sulfisoxazole.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Sulfisoxazole.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Sulfisoxazole.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Sulfisoxazole.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Sulfisoxazole.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Sulfisoxazole.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Sulfisoxazole.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Sulfisoxazole.
PioglitazonePioglitazone may increase the hypoglycemic activities of Sulfisoxazole.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Sulfisoxazole.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Sulfisoxazole.
PirlindolePirlindole may increase the hypoglycemic activities of Sulfisoxazole.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Sulfisoxazole.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Sulfisoxazole.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Sulfisoxazole.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Sulfisoxazole.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Sulfisoxazole.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Sulfisoxazole.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Sulfisoxazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Sulfisoxazole.
PramlintidePramlintide may increase the hypoglycemic activities of Sulfisoxazole.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Sulfisoxazole.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Sulfisoxazole.
PrazepamThe metabolism of Prazepam can be decreased when combined with Sulfisoxazole.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Sulfisoxazole.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Sulfisoxazole.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Sulfisoxazole.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Sulfisoxazole.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Sulfisoxazole.
PrimidoneThe metabolism of Sulfisoxazole can be increased when combined with Primidone.
ProcainamideSulfisoxazole may increase the QTc-prolonging activities of Procainamide.
ProcaineThe therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Procaine.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Sulfisoxazole.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Sulfisoxazole.
ProguanilThe metabolism of Proguanil can be decreased when combined with Sulfisoxazole.
PromazinePromazine may increase the QTc-prolonging activities of Sulfisoxazole.
PromazineThe metabolism of Promazine can be decreased when combined with Sulfisoxazole.
PromethazinePromethazine may increase the QTc-prolonging activities of Sulfisoxazole.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Sulfisoxazole.
PropafenonePropafenone may increase the QTc-prolonging activities of Sulfisoxazole.
PropofolPropofol may increase the QTc-prolonging activities of Sulfisoxazole.
PropofolThe metabolism of Propofol can be decreased when combined with Sulfisoxazole.
PropranololThe metabolism of Propranolol can be decreased when combined with Sulfisoxazole.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Sulfisoxazole.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Sulfisoxazole.
PyrimethamineThe metabolism of Sulfisoxazole can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Sulfisoxazole.
QuetiapineSulfisoxazole may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Sulfisoxazole.
QuinidineSulfisoxazole may increase the QTc-prolonging activities of Quinidine.
QuinineSulfisoxazole may increase the QTc-prolonging activities of Quinine.
QuinineQuinine may increase the hypoglycemic activities of Sulfisoxazole.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Sulfisoxazole.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Sulfisoxazole.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Sulfisoxazole.
RanolazineRanolazine may increase the QTc-prolonging activities of Sulfisoxazole.
RanolazineThe metabolism of Ranolazine can be decreased when combined with Sulfisoxazole.
RasagilineRasagiline may increase the hypoglycemic activities of Sulfisoxazole.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Sulfisoxazole.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Sulfisoxazole.
RepaglinideRepaglinide may increase the hypoglycemic activities of Sulfisoxazole.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Sulfisoxazole.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Sulfisoxazole.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Sulfisoxazole.
RifapentineThe metabolism of Sulfisoxazole can be increased when combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Sulfisoxazole.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Sulfisoxazole.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Sulfisoxazole.
RiociguatThe metabolism of Riociguat can be decreased when combined with Sulfisoxazole.
RisperidoneRisperidone may increase the QTc-prolonging activities of Sulfisoxazole.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Sulfisoxazole.
RitonavirRitonavir may increase the QTc-prolonging activities of Sulfisoxazole.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Sulfisoxazole.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Sulfisoxazole.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Sulfisoxazole.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Sulfisoxazole.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Sulfisoxazole.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Sulfisoxazole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Sulfisoxazole.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Sulfisoxazole.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Sulfisoxazole.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Sulfisoxazole.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Sulfisoxazole.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Sulfisoxazole.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Sulfisoxazole.
SafrazineSafrazine may increase the hypoglycemic activities of Sulfisoxazole.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Sulfisoxazole.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Sulfisoxazole.
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Sulfisoxazole.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Sulfisoxazole.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Sulfisoxazole.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Sulfisoxazole.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Sulfisoxazole.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Sulfisoxazole.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Sulfisoxazole.
SecobarbitalThe metabolism of Sulfisoxazole can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypoglycemic activities of Sulfisoxazole.
SelegilineThe metabolism of Selegiline can be decreased when combined with Sulfisoxazole.
SelexipagThe metabolism of Selexipag can be decreased when combined with Sulfisoxazole.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Sulfisoxazole.
SertindoleThe metabolism of Sertindole can be decreased when combined with Sulfisoxazole.
SertralineSertraline may increase the hypoglycemic activities of Sulfisoxazole.
SertralineThe metabolism of Sertraline can be decreased when combined with Sulfisoxazole.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Sulfisoxazole.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Sulfisoxazole.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Sulfisoxazole.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Sulfisoxazole.
SilodosinThe metabolism of Silodosin can be decreased when combined with Sulfisoxazole.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Sulfisoxazole.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Sulfisoxazole.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Sulfisoxazole.
SitagliptinSitagliptin may increase the hypoglycemic activities of Sulfisoxazole.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Sulfisoxazole.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Sulfisoxazole.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Sulfisoxazole.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Sulfisoxazole.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Sulfisoxazole.
SorafenibSorafenib may increase the QTc-prolonging activities of Sulfisoxazole.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Sulfisoxazole.
SotalolSulfisoxazole may increase the QTc-prolonging activities of Sotalol.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Sulfisoxazole.
StanozololStanozolol may increase the hypoglycemic activities of Sulfisoxazole.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Sulfisoxazole.
SulfadiazineSulfisoxazole may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Sulfisoxazole.
SulfamethoxazoleSulfisoxazole may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Sulfisoxazole.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Sulfisoxazole.
SulodexideSulodexide may increase the hypoglycemic activities of Sulfisoxazole.
SunitinibSunitinib may increase the QTc-prolonging activities of Sulfisoxazole.
SunitinibSulfisoxazole may increase the hypoglycemic activities of Sunitinib.
SuprofenThe metabolism of Suprofen can be decreased when combined with Sulfisoxazole.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Sulfisoxazole.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Sulfisoxazole.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Sulfisoxazole.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Sulfisoxazole.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Sulfisoxazole.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Sulfisoxazole.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Sulfisoxazole.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Sulfisoxazole.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Sulfisoxazole.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Sulfisoxazole.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Sulfisoxazole.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Sulfisoxazole.
TelavancinSulfisoxazole may increase the QTc-prolonging activities of Telavancin.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Sulfisoxazole.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Sulfisoxazole.
TemazepamThe metabolism of Temazepam can be decreased when combined with Sulfisoxazole.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Sulfisoxazole.
TeniposideThe metabolism of Teniposide can be decreased when combined with Sulfisoxazole.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Sulfisoxazole.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Sulfisoxazole.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Sulfisoxazole.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Sulfisoxazole.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Sulfisoxazole.
TestosteroneTestosterone may increase the hypoglycemic activities of Sulfisoxazole.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Sulfisoxazole.
TetrabenazineSulfisoxazole may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Sulfisoxazole.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Sulfisoxazole.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sulfisoxazole.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Sulfisoxazole.
ThiopentalThe therapeutic efficacy of Thiopental can be increased when used in combination with Sulfisoxazole.
ThioridazineSulfisoxazole may increase the QTc-prolonging activities of Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Sulfisoxazole.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Sulfisoxazole.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Sulfisoxazole.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Sulfisoxazole.
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Sulfisoxazole.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Sulfisoxazole.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Sulfisoxazole.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Sulfisoxazole.
TizanidineTizanidine may increase the QTc-prolonging activities of Sulfisoxazole.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Sulfisoxazole.
TolazamideSulfisoxazole may increase the hypoglycemic activities of Tolazamide.
TolbutamideSulfisoxazole may increase the hypoglycemic activities of Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Sulfisoxazole.
TolterodineTolterodine may increase the QTc-prolonging activities of Sulfisoxazole.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Sulfisoxazole.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Sulfisoxazole.
TorasemideThe metabolism of Torasemide can be decreased when combined with Sulfisoxazole.
ToremifeneSulfisoxazole may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Sulfisoxazole.
TramadolThe metabolism of Tramadol can be decreased when combined with Sulfisoxazole.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sulfisoxazole.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Sulfisoxazole.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Sulfisoxazole.
TrazodoneTrazodone may increase the hypoglycemic activities of Sulfisoxazole.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Sulfisoxazole.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Sulfisoxazole.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Sulfisoxazole.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Sulfisoxazole.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Sulfisoxazole.
TriazolamThe metabolism of Triazolam can be decreased when combined with Sulfisoxazole.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Sulfisoxazole.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Sulfisoxazole.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Sulfisoxazole.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Sulfisoxazole.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Sulfisoxazole.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Sulfisoxazole.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Sulfisoxazole.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Sulfisoxazole.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Sulfisoxazole.
UdenafilThe metabolism of Udenafil can be decreased when combined with Sulfisoxazole.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Sulfisoxazole.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Sulfisoxazole.
Valproic AcidThe metabolism of Sulfisoxazole can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Sulfisoxazole can be decreased when combined with Valsartan.
VandetanibSulfisoxazole may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Sulfisoxazole.
VardenafilVardenafil may increase the QTc-prolonging activities of Sulfisoxazole.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Sulfisoxazole.
VemurafenibSulfisoxazole may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Sulfisoxazole.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Sulfisoxazole.
VerapamilThe metabolism of Verapamil can be decreased when combined with Sulfisoxazole.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Sulfisoxazole.
VilanterolVilanterol may increase the QTc-prolonging activities of Sulfisoxazole.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Sulfisoxazole.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Sulfisoxazole.
VilazodoneVilazodone may increase the hypoglycemic activities of Sulfisoxazole.
VildagliptinVildagliptin may increase the hypoglycemic activities of Sulfisoxazole.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Sulfisoxazole.
VincristineThe metabolism of Vincristine can be decreased when combined with Sulfisoxazole.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Sulfisoxazole.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Sulfisoxazole.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Sulfisoxazole.
VogliboseVoglibose may increase the hypoglycemic activities of Sulfisoxazole.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Sulfisoxazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Sulfisoxazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Sulfisoxazole.
VortioxetineVortioxetine may increase the hypoglycemic activities of Sulfisoxazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Sulfisoxazole.
WarfarinThe metabolism of Warfarin can be decreased when combined with Sulfisoxazole.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Sulfisoxazole.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Sulfisoxazole.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Sulfisoxazole.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Sulfisoxazole.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Sulfisoxazole.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Sulfisoxazole.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Sulfisoxazole.
ZileutonThe metabolism of Zileuton can be decreased when combined with Sulfisoxazole.
ZimelidineZimelidine may increase the hypoglycemic activities of Sulfisoxazole.
ZiprasidoneSulfisoxazole may increase the QTc-prolonging activities of Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Sulfisoxazole.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Sulfisoxazole.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Sulfisoxazole.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Sulfisoxazole.
ZuclopenthixolSulfisoxazole may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives.
Gene Name:
folP
Uniprot ID:
P0AC13
Molecular Weight:
30614.855 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Jorgensen JH, Crawford SA, Fiebelkorn KR: Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. J Clin Microbiol. 2005 Jul;43(7):3162-71. [PubMed:16000430 ]
  3. Fiebelkorn KR, Crawford SA, Jorgensen JH: Mutations in folP associated with elevated sulfonamide MICs for Neisseria meningitidis clinical isolates from five continents. Antimicrob Agents Chemother. 2005 Feb;49(2):536-40. [PubMed:15673729 ]
  4. Hong YL, Hossler PA, Calhoun DH, Meshnick SR: Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63. [PubMed:7486915 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23